Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAdamo, Barbara
dc.contributor.authorBellet Ezquerra, Meritxell
dc.contributor.authorParé, Laia
dc.contributor.authorPascual, Tomás
dc.contributor.authorVidal, Maria
dc.contributor.authorPérez Fidalgo, José A
dc.contributor.authorGómez Pardo, Patricia
dc.date.accessioned2020-07-08T12:04:08Z
dc.date.available2020-07-08T12:04:08Z
dc.date.issued2019-09-18
dc.identifier.citationAdamo B, Bellet M, Paré L, Pascual T, Vidal M, Pérez Fidalgo JA, et al. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Res. 2019 Sep 18;21(1):108.
dc.identifier.issn1465-542X
dc.identifier.urihttp://hdl.handle.net/11351/5073
dc.descriptionCàncer de mama; Quimioteràpia metronòmica; Vinorelbina
dc.description.sponsorshipThis study was supported by a grant from Pierre-Fabre. Pierre-Fabre had no role in the management of this trial. The decisions and responsibilities of this trial were all under the sponsor: SOLTI Group.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesBreast Cancer Research;21(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMarcadors tumorals
dc.subjectMedicaments antineoplàstics
dc.subjectMama - Càncer - Tractament
dc.subject.meshBreast Neoplasms
dc.subject.meshBiomarkers, Tumor
dc.subject.meshVinorelbine
dc.subject.mesh/drug therapy
dc.titleOral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13058-019-1195-z
dc.subject.decsneoplasias de la mama
dc.subject.decsmarcadores tumorales
dc.subject.decsvinorelbina
dc.subject.decs/tratamiento farmacológico
dc.relation.publishversionhttps://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1195-z
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Adamo B, Vidal M] Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. [Bellet M, Gómez-Pardo P] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Paré L] Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pascual T] Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pérez Fidalgo JA] Hospital Clínico Universitario de Valencia, Valencia, Spain. INCLIVA Instituto de Investigación Sanitaria, Universitat de València, Valencia, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain
dc.identifier.pmid31533777
dc.identifier.wos000487022700002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple